StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) operating KPIs

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)

Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%

Merck daiichi Sankyo (3 DXd ADC Oncology Programs) — Net R&D cost-sharing expense ($M) ($M)

Form 10-Q / 10-K Note 3/4 Collaborative Arrangements

QuarterlyAnnual
Latest, Q2 2026
181
Period ended Jun 30, 2026
Change on a year earlier
-6.2%
193 in Q2 2025
History
14 quarters
Since Q1 2023
Sources
9
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedDaiichi Sankyo (3 DXd ADC Oncology Programs) — Net R&D cost-sharing expense ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026181-6.2%Form 10-Q (filed 2026-08-07) ↗
Q1 2026Mar 31, 2026160+25.0%Form 10-Q (filed 2026-05-04) ↗
Q4 2025Dec 31, 2025145+16.9%Form 10-K (filed 2026-02-24) ↗
Q3 2025Sep 30, 2025110+17.0%Form 10-Q (filed 2025-11-05) ↗
Q2 2025Jun 30, 2025193+196.9%Form 10-Q (filed 2026-08-07) ↗
Q1 2025Mar 31, 2025128+85.5%Form 10-Q (filed 2026-05-04) ↗
Q4 2024Dec 31, 2024124-97.7%Form 10-K (filed 2026-02-24) ↗
Q3 2024Sep 30, 202494–Form 10-Q (filed 2025-11-05) ↗
Q2 2024Jun 30, 202465–Form 10-Q (filed 2025-08-05) ↗
Q1 2024Mar 31, 202469–Form 10-Q (filed 2025-05-02) ↗
Q4 2023Dec 31, 20235,500–Form 10-Q (filed 2024-11-06) ↗
Q3 2023Sep 30, 20230–Form 10-Q (filed 2024-11-06) ↗
Q2 2023Jun 30, 20230–Form 10-Q (filed 2024-08-05) ↗
Q1 2023Mar 31, 20230–Form 10-Q (filed 2024-05-03) ↗

Cite this data

StockData. (2026). Merck Daiichi Sankyo (3 DXd ADC Oncology Programs) — Net R&D cost-sharing expense ($M) ($M), quarterly Q1 2023–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/collab_daiichisankyo_rd

See every metric in the Merck KPI table. Data updated Oct 26, 2026.